

PRESIDENT'S REPORT 2019

In 2019, the Canadian Association of Nuclear Medicine continued its efforts to promote the added value of nuclear medicine both at the Canadian and international levels. Nuclear medicine is a small field but very dynamic.

On the Canadian scene, the CANM has continued its involvement at the federal and provincial levels of government over the past year. The Association focused on regulation and the need for investments to make available to Canadian patients, new radiotracers and equipment in both PET-CT and SPECT-CT. We support the position that each Canadian nuclear medicine unit should have at least one SPECT-CT camera and one PET-CT camera.

These technologies have become essential for the diagnosis and follow-up of several diseases, whether in cancer, neuro-degenerative diseases or cardiac and infectious diseases. Quebec's success in these developments is remarkable and has become a reference point for other provinces in Canada.

Our partnership with our industrial colleagues is crucial to the development and advancement of new tests and treatments that can be offered to patients. In this context, in 2019, we held two forums with our industry partners in addition to our annual conference, which was held with great success in Québec City.

The CANM has also been involved in the proposal to amend the training program for our residents at the Royal College to better reflect the new challenges of practicing nuclear medicine in both hybrid technology and theranostics. In the face of all these developments, the need for more nuclear medical specialists and technologists grows year after year.

The CANM has been actively involved in promoting the recruitment of these colleagues.

In addition, the CANM continued to work closely with *The Patient* and the *E Patient* magazines to raise awareness of nuclear medicine among prescribers, the general public and our government decision-makers. Guidelines are also being developed on various topics, the last one to be completed in the spring of 2020 will be the imaging of the DOPAMINE transportation system in the assessment of movement disorders. The CANM has become a very active partner on the international scene by formally participating in committees within the International Atomic Energy Agency (IAEA), the European Nuclear Medicine Association (EANM), the American Nuclear Medicine Association (SNMMI), the Oceanic and Asian Federation of Nuclear Medicine and Biology (AOFNMB), the Arab Nuclear Medicine Society (ARSNM), the Latin American Association of Nuclear Medicine (ALASBIMN), the American Association of Nuclear Cardiology (ASNC) and finally the World Federation of Nuclear Medicine and Biology (WFNMB), of which one of our former presidents, Jean-Luc Urbain, was elected to be the next president.

Finally, I want to thank all the members of the Board of Directors and all our members of the Association who have so generously agreed to offer us their expertise and time. I would

particularly like to acknowledge the contribution of our administrative director, H  l  ne Samson, for his availability and competence. Thanks also to Christiane Kingsbury, who on several occasions has offered H  l  ne valuable help.

In 2019, the CANM had a very active and productive year, and it is with conviction that the CANM is eagerly preparing for the new challenges of 2020.

The President
Fran  ois Lamoureux.